Taiwan Liposome Company Ltd - ADR

Liposome Company manufactures commercialized drug delivery systems based on liposomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual Meeting last week. TLC599 is an investigational therapy developed by TLC BioSciences for osteoarthritis knee pain. In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis, introduced TLC599, and presented data showing TLC599's potential to be a better treatment for managing osteoarthritis knee pain than currently available treatments.

Highlights of Dr. David Hunter's Oral Presentation at ACR's Late Breaking Abstracts Session

Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

One of the largest deals seen in Taiwan's biotech sector One of the largest deals seen in Taiwan's biotech sector

TLC Announces TLC599 Agreement with Endo

TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication use TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication use

TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

TAIPEI, Taiwan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company or TLC (Nasdaq: TLC, TWO: 4152, “the Company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that it has notified Nasdaq that it will apply for the voluntary delisting of its American depositary shares (“ADS”s) from the Nasdaq Global Market.

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

G Medical Innovations Holdings Ltd

Newegg Commerce

Exela Technologies

Trxade Group

Looking for the next AMC, retail investors are on the hunt for the next squeeze. Here are five short squeeze stocks to watch this week.

Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop

TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company's board-approved stock swap transactions with Woods Investment Company, Ltd. (“Woods”) at a press conference held at 4:00pm Taipei time at the Taipei Exchange (TPEx). Details of the stock swap transactions are as follows:

TLC Announces Details of Stock Swap Transactions

The stock price of TLC (Nasdaq: TLC) increased by 28.69% yesterday. This is why it happened.

TLC Stock Price: 28.69% Increase Explanation

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average.

Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?

Joint

SemiLEDs

Moxian BVI

Scopus BioPharma

These are 5 of the best stock gainers this past week that you should know about: SCPS, TLC, LEDS, JYNT, MOXC. The post 5 Stock Gainers This Past Week: SCPS, TLC, LEDS, JYNT, MOXC appeared first on Pulse 2.0.

5 Stock Gainers This Past Week: SCPS, TLC, LEDS, JYNT, MOXC

India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage. AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus.

TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

The stock price of Taiwan Liposome Company (NASDAQ: TLC) increased by over 6% pre-market. This is why it happened.

TLC Stock Price: Over 6% Increase Pre-Market Explanation

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India) for immediate importation per approved usage and indication, to aid in the country's emergency of acute liposomal amphotericin B shortage.

TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

Ngm Biopharmaceuticals Inc

Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.

Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today

The stock price of Taiwan Liposome Company (NASDAQ: TLC) increased by over 15% during intraday trading this morning. This is why it happened.

TLC Stock Price: Over 15% Increase Explanation

InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress. InspirMed is a subsidiary of Taiwan Liposome Company (NASDAQ: TLC), specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases.

Taiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine (ISAM) Congress. Pharmacokinetic studies on inhalable liposomal GS-441524 (named ISPM21) and inhalable liposomal hydroxychloroquine (named ISPM19) showed significantly higher concentrations in the lungs than their conventional counterparts, giving ISPM21 and ISPM19 potential as prophylaxis and/or treatment for COVID-19.

InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

TLC Reports First Quarter 2021 Financial Results and Provides Business Update

Praised as benchmark for small and medium-sized enterprises Praised as benchmark for small and medium-sized enterprises

TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of inhalable liposome formulation programs, announced today that a late-breaking abstract describing the potential advantages of ISPM21 and ISPM19 has been accepted by the scientific committee for poster presentation at the 23rd International Society for Aerosols in Medicine (ISAM) Congress.

InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company's management team will be presenting at the following virtual investor conferences:

TLC to Present at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the fiscal year ended December 31, 2020 and provided a business update.

TLC Reports Fiscal Year End 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., has completed a round of financing, raising US$15 million in cash from strategic investors in exchange for subsidiary equity.

News for Taiwan Liposome Company Ltd - ADR Stock (TLC)